波士顿科学Boston Scientific Corporation (BSX) 2015年年度报告「NYSE」.pdf

1、BOSTON SCIENTIFIC 2015 ANNUAL REPORTTRANSFORMING LIVES.3/9/16 4:01 PMFINANCIAL HIGHLIGHTSThroughout this Annual Report,unless otherwise noted,all revenue and other growth rates represent 2015 growth compared to 2014.Information on or connected to our website(or the website of any third party)referen

2、ced in this Annual Report is in addition to and not a part of or incorporated by reference into this Annual Report.1 Operational sales/revenue and growth rates are non-GAAP measures that exclude the impact of sales from divested businesses and changes in foreign currency exchange rates;see reconcili

3、ation to GAAP sales/revenue and growth rates on pages 9 and 10.2 Organic revenue growth excludes the impact of sales from divested businesses,changes in foreign currency exchange rates and sales from the acquisitions of the interventional business of Bayer AG and the American Medical Systems male ur

4、ology portfolio over the prior year period.3 Adjusted operating margin,and adjusted earnings per share and growth rates are non-GAAP measures that exclude goodwill and other intangible asset impairment charges,acquisition and divestiture-related net charges,litigation-related charges,restructuring a

5、nd restructuring-related charges,pension termination charges,discrete tax items and amortization expense.2015 OPERATIONAL SALES BY PRODUCT CATEGORY1(Dollars in millions)2015 Growth CARDIOVASCULAR Interventional Cardiology$2,242 7%Peripheral Interventions97513%RHYTHM Cardiac Rhythm Management1,9341%M

6、ANAGEMENT Electrophysiology 248 9%MEDSURG Endoscopy 1,422 6%Urology and Pelvic Health73536%Neuromodulation 512 8%$8,068 8%2015 OPERATIONAL SALES BY REGION1(Dollars in millions)2015 Growth U.S.$4,223 9%Europe1,7808%Asia,Middle East and Africa(AMEA)1,616 7%Other4497%$8,068 8%OPERATIONAL REVENUE GROWTH